morphine and diazepam

Pharmacodynamic interaction: both drugs produce central nervous system (CNS) depression. Morphine activates mu-opioid receptors, while diazepam enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors. The additive effect on respiratory centers in the brainstem and on level of consciousness results in synergistic CNS and respiratory depression.

Co-administration increases the risk of profound sedation, respiratory depression, coma, and death. The effects are dose-dependent and more pronounced in the elderly, in patients with compromised respiratory function, or when other CNS depressants are used. Respiratory depression may be delayed and prolonged, requiring close monitoring.

Avoid concomitant use unless absolutely necessary. If co-prescribed, prescribe the lowest effective doses for the shortest duration, monitor vital signs and level of consciousness frequently, and ensure that naloxone and resuscitative equipment are immediately available. Dose reduction of one or both agents may be required. Warn patients and caregivers about the signs of respiratory depression and excessive sedation.

The additive CNS and respiratory depressant effects of opioids and benzodiazepines are well documented in clinical practice and supported by large observational studies and regulatory warnings. This interaction is widely recognized as a major safety concern, leading to boxed warnings in many countries.